Boston Scientific Operating Margin 2010-2025 | BSX
Current and historical operating margin for Boston Scientific (BSX) over the last 10 years. The current operating profit margin for Boston Scientific as of June 30, 2025 is 22.86%.
| Boston Scientific Operating Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Operating Income | Operating Margin |
| 2025-06-30 | $18.50B | $3.15B | 17.05% |
| 2025-03-31 | $17.55B | $2.85B | 16.26% |
| 2024-12-31 | $16.75B | $2.61B | 15.56% |
| 2024-09-30 | $15.91B | $2.51B | 15.79% |
| 2024-06-30 | $15.23B | $2.47B | 16.23% |
| 2024-03-31 | $14.71B | $2.47B | 16.76% |
| 2023-12-31 | $14.24B | $2.34B | 16.45% |
| 2023-09-30 | $13.76B | $2.16B | 15.69% |
| 2023-06-30 | $13.40B | $1.82B | 13.61% |
| 2023-03-31 | $13.05B | $1.73B | 13.28% |
| 2022-12-31 | $12.68B | $1.65B | 12.99% |
| 2022-09-30 | $12.57B | $1.43B | 11.35% |
| 2022-06-30 | $12.33B | $1.46B | 11.80% |
| 2022-03-31 | $12.16B | $1.30B | 10.65% |
| 2021-12-31 | $11.89B | $1.20B | 10.08% |
| 2021-09-30 | $11.47B | $1.07B | 9.32% |
| 2021-06-30 | $11.20B | $0.48B | 4.25% |
| 2021-03-31 | $10.12B | $0.14B | 1.42% |
| 2020-12-31 | $9.91B | $-0.08B | -0.80% |
| 2020-09-30 | $10.11B | $0.08B | 0.78% |
| 2020-06-30 | $10.16B | $0.67B | 6.58% |
| 2020-03-31 | $10.79B | $1.12B | 10.40% |
| 2019-12-31 | $10.74B | $1.52B | 14.13% |
| 2019-09-30 | $10.39B | $1.63B | 15.65% |
| 2019-06-30 | $10.08B | $1.63B | 16.19% |
| 2019-03-31 | $9.94B | $1.64B | 16.49% |
| 2018-12-31 | $9.82B | $1.51B | 15.33% |
| 2018-09-30 | $9.67B | $1.51B | 15.58% |
| 2018-06-30 | $9.50B | $1.50B | 15.74% |
| 2018-03-31 | $9.27B | $1.33B | 14.34% |
| 2017-12-31 | $9.05B | $1.29B | 14.20% |
| 2017-09-30 | $8.83B | $1.11B | 12.53% |
| 2017-06-30 | $8.71B | $1.08B | 12.36% |
| 2017-03-31 | $8.58B | $0.52B | 6.04% |
| 2016-12-31 | $8.39B | $0.45B | 5.33% |
| 2016-09-30 | $8.17B | $0.08B | 0.98% |
| 2016-06-30 | $7.96B | $-0.57B | -7.13% |
| 2016-03-31 | $7.67B | $-0.01B | -0.18% |
| 2015-12-31 | $7.48B | $-0.28B | -3.78% |
| 2015-09-30 | $7.39B | $-0.55B | -7.43% |
| 2015-06-30 | $7.34B | $-0.19B | -2.53% |
| 2015-03-31 | $7.37B | $-0.47B | -6.43% |
| 2014-12-31 | $7.38B | $-0.30B | -4.08% |
| 2014-09-30 | $7.33B | $0.32B | 4.35% |
| 2014-06-30 | $7.22B | $0.36B | 4.96% |
| 2014-03-31 | $7.16B | $0.65B | 9.04% |
| 2013-12-31 | $7.14B | $0.12B | 1.68% |
| 2013-09-30 | $7.13B | $0.11B | 1.54% |
| 2013-06-30 | $7.13B | $-0.59B | -8.24% |
| 2013-03-31 | $7.14B | $-4.39B | -61.51% |
| 2012-12-31 | $7.25B | $-3.87B | -53.36% |
| 2012-09-30 | $7.28B | $-3.81B | -52.41% |
| 2012-06-30 | $7.42B | $-3.05B | -41.07% |
| 2012-03-31 | $7.56B | $0.78B | 10.29% |
| 2011-12-31 | $7.62B | $0.90B | 11.86% |
| 2011-09-30 | $7.78B | $1.08B | 13.90% |
| 2011-06-30 | $7.82B | $1.16B | 14.81% |
| 2011-03-31 | $7.77B | $1.15B | 14.82% |
| 2010-12-31 | $7.81B | $-0.66B | -8.40% |
| 2010-09-30 | $7.88B | $-2.24B | -28.35% |
| 2010-06-30 | $7.99B | $-2.44B | -30.47% |
| 2010-03-31 | $8.14B | $-2.39B | -29.38% |
| 2009-12-31 | $8.19B | $-0.89B | -10.92% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $156.325B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.889B | 27.07 |
| Stryker (SYK) | United States | $149.639B | 30.46 |
| EssilorLuxottica (ESLOY) | France | $141.259B | 0.00 |
| Medtronic (MDT) | Ireland | $119.046B | 16.78 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.750B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.937B | 25.13 |
| ResMed (RMD) | United States | $40.192B | 28.75 |
| Agilent Technologies (A) | United States | $35.696B | 23.06 |
| GE HealthCare Technologies (GEHC) | United States | $33.662B | 15.82 |
| Terumo (TRUMY) | Japan | $26.606B | 31.53 |
| Koninklijke Philips (PHG) | Netherlands | $26.557B | 17.57 |
| Insulet (PODD) | United States | $23.925B | 80.16 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.018B | 13.38 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.402B | 0.00 |
| Baxter (BAX) | United States | $12.681B | 9.80 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.061B | 29.61 |
| Lantheus Holdings (LNTH) | United States | $3.733B | 10.09 |
| Envista Holdings (NVST) | United States | $3.520B | 24.63 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.349B | 14.86 |
| Perrigo (PRGO) | Ireland | $3.266B | 8.16 |
| ICU Medical (ICUI) | United States | $3.151B | 21.45 |
| Haemonetics (HAE) | United States | $2.628B | 11.73 |
| Acuren (TIC) | United States | $2.261B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $2.213B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.159B | 46.29 |
| QuidelOrtho (QDEL) | United States | $1.948B | 12.26 |
| Green Thumb Industries (GTBIF) | United States | $1.840B | 79.00 |
| AtriCure (ATRC) | United States | $1.838B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.519B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.503B | 17.74 |
| AdaptHealth (AHCO) | United States | $1.284B | 18.25 |
| Neogen (NEOG) | United States | $1.249B | 19.83 |
| BioLife Solutions (BLFS) | United States | $1.200B | 2505.00 |
| InMode (INMD) | Israel | $0.944B | 8.74 |
| Kestra Medical Technologies (KMTS) | United States | $0.829B | 0.00 |
| Valneva SE (VALN) | France | $0.753B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.740B | 0.00 |
| SNDL (SNDL) | Canada | $0.704B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.618B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.615B | 0.00 |
| ZimVie (ZIMV) | United States | $0.532B | 20.52 |
| Evolus (EOLS) | United States | $0.494B | 0.00 |
| Surmodics (SRDX) | United States | $0.487B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.479B | 16.50 |
| CeriBell (CBLL) | United States | $0.434B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.432B | 0.00 |
| Owens & Minor (OMI) | United States | $0.379B | 3.36 |
| Sanuwave Health (SNWV) | United States | $0.357B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.352B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.306B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.300B | 0.00 |
| Brainsway (BWAY) | Israel | $0.294B | 59.85 |
| High Tide (HITI) | Canada | $0.292B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.287B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.286B | 21.68 |
| Omeros (OMER) | United States | $0.283B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.260B | 0.00 |
| Cerus (CERS) | United States | $0.251B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.242B | 0.00 |
| Organigram Global (OGI) | Canada | $0.232B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.219B | 0.00 |
| Exagen (XGN) | United States | $0.217B | 0.00 |
| Quanterix (QTRX) | United States | $0.211B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.199B | 16.63 |
| FitLife Brands (FTLF) | United States | $0.175B | 0.00 |
| Biote (BTMD) | United States | $0.170B | 5.64 |
| Jushi Holdings (JUSHF) | United States | $0.149B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.114B | 0.00 |
| MacroGenics (MGNX) | United States | $0.112B | 0.00 |
| Jin Medical (ZJYL) | China | $0.111B | 0.00 |
| Fonar (FONR) | United States | $0.099B | 12.78 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.090B | 0.00 |
| Apyx Medical (APYX) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.062B | 0.00 |
| MariMed (MRMD) | United States | $0.060B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.059B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.059B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 33.68 |
| Zynex (ZYXI) | United States | $0.050B | 0.00 |
| Veru (VERU) | United States | $0.048B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| Nephros (NEPH) | United States | $0.040B | 31.08 |
| United-Guardian (UG) | United States | $0.039B | 15.02 |
| Senestech (SNES) | United States | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Cellectar Biosciences (CLRB) | United States | $0.016B | 0.00 |
| Sharps Technology (STSS) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |